Equity Research Pharmaceutical Preparations

Should You Buy Amphastar Pharmaceuticals, Inc. Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Amphastar Pharmaceuticals, Inc. (AMPH) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 10.0/10. At a current price of $19.63, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.

The short answer: 11 of 13 CirclFi valuation models project upside for Amphastar Pharmaceuticals, Inc. (AMPH) at $19.63 — the model consensus leans bullish, with a Quality Score of 10.0/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 11 of 13 models see upside — majority bullish
  • Quality Score: 10.0/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $3.25 – $76.62 (2254% spread)

Bullish Models

11 / 13

Bearish Models

2 / 13

Quality Score

10.0 /10

Excellent — top-tier fundamentals

Value Trap Risk

— /100
Not scored

Not scored

Model Consensus

13 /13
Active Models

Avg. confidence: 47%

Investment Thesis

The Bull Case

Target: $76.62 (+290.3% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Amphastar Pharmaceuticals, Inc.'s rating of 10.0/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably.
  • According to the CirclFi Deep Alpha Valuation Engine, 11 of 13 models identify upside from $19.63 to a composite fair value of $40.69, indicating the market hasn't fully priced in Amphastar Pharmaceuticals, Inc.'s earnings power.
  • According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $76.62 (+290.3%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.
  • Industry tailwind: orphan drug designation could provide meaningful support for Amphastar Pharmaceuticals, Inc.'s revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $3.25 (-83.4%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $3.25 (-83.4%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +373.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: patent expiration revenue loss represents a meaningful risk for Amphastar Pharmaceuticals, Inc. and its Pharmaceutical Preparations peers.

Peer Benchmarking

AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0
SIGA SIGA Technologies In
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

2254%

Fair Value Range

$3.25 – $76.62

A 2254% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

First Chicago

$76.62 (+290.3%)

Most Bearish

Dynamic NAV

$3.25 (-83.4%)

Key Risk Factors

Model Disagreement

2254% spread signals high variance in projections.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View AMPH Data Page →

The Bottom Line

The convergence of 10.0/10 quality, multi-model undervaluation (11/13 bullish, +107.3% avg. upside), and a composite fair value of $40.69 vs. $19.63 current price makes Amphastar Pharmaceuticals, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.

These are quantitative model outputs, not investment recommendations. Amphastar Pharmaceuticals, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy AMPH stock right now?

Based on CirclFi's multi-model analysis, 11 of 13 models see upside for AMPH at $19.63. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 10.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Amphastar Pharmaceuticals, Inc.?

Key risks include: wide model disagreement (2254% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does AMPH compare to its competitors?

Among Pharmaceutical Preparations peers, AMPH holds a Quality Score of 10.0/10. Comparable companies include AZN (QOC 10.0), CPRX (QOC 10.0), HRMY (QOC 10.0). The relative ranking helps investors identify whether AMPH offers better fundamental quality than alternatives in the same sector.

Is AMPH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AMPH's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy AMPH at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $3.25 to $76.62. At $19.63, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for AMPH.

View AMPH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →